Trial · NCT03417141
Valchlor in the Treatment of Lichen Planopilaris
NCT03417141, Phase 2, Completed, Mayo Clinic; results first posted 2020-07-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Valchlor in the Treatment of Lichen Planopilaris. Trials, record NCT03417141. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03417141
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Valchlor in the Treatment of Lichen Planopilaris
- NCT number
- NCT03417141
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Lichen Planopilaris
- Interventions
- Mechlorethamine 0.016% Top Gel
- First posted
- 2018-01-31
- Last updated
- 2021-01-28
- Results first posted
- 2020-07-02
- Limitations and caveats
- One subject withdrew and three subjects were non-compliant with study procedures. Data was not analyzed for a total of four subjects.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Lichen Planopilaris Activity Index (LLPAI) | baseline, up to 24 weeks | The Lichen Planopilaris Activity Index is a standardized validated quantitative measure of disease activity. LPPAI score (0-10) is calculated as follows: (pruritus + pain + burning)/3 + (scalp erythema + perifollicular erythema + perifollicular scale)/3 + 2.5 (pull test) + 1.5 (spreading/2). Symptoms and signs are graded on a 4-point scale with 0 = absent, 1 = mild, 2 = moderate, and 3 =severe. Clinical progression and a positive hair pull test are graded 1=yes; 0=no. The percent change of LLPAI score from before and after treatment. |
| Secondary | Change in Dermatology Quality of Life Index (DQLI) | baseline, 24 weeks | The DQLI is 10 standardized items measuring impact of skin disease rated as 0=not at all/not relevant; 1=a little; 2=a lot; 3=very much. The absolute change of total DQLI score from before and after treatment |
| Secondary | Change in Follicular Units | baseline, 24 weeks | Phototrichograms of all subjects scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total number of hairs per square cm was measured before and after treatment. |
| Secondary | Change in Mean Follicular Density | baseline, 24 weeks | Phototrichograms of all subjects scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the mean number of follicular units per square cm was measured before and after treatment. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Lichen Planopilaris Activity Index (LLPAI) | baseline, up to 24 weeks | One subject withdrew and data was not analyzed for that subject | percentage of change from baseline | MEDIAN |
| SECONDARY | Change in Dermatology Quality of Life Index (DQLI) | baseline, 24 weeks | One subject withdrew and three subjects were non-compliant with study procedures. Data was not analyzed for a total of four subjects. | score on a scale | MEDIAN |
| SECONDARY | Change in Follicular Units | baseline, 24 weeks | One subject withdrew, and three subjects were non-compliant with study procedures. Data was not was not analyzed for a total of four subjects. | percent change | MEDIAN |
| SECONDARY | Change in Mean Follicular Density | baseline, 24 weeks | One subject withdrew and three subjects were non-compliant with study procedures. Data was not analyzed for a total of four subjects. | percent change | MEDIAN |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Lichen Planopilaris Activity Index (LLPAI) | Valchor Treatment of Lichen Planopilaris | Week 12 | -42.9 | Full Range -100.0 to 33.3 | percentage of change from baseline |
| Change in Lichen Planopilaris Activity Index (LLPAI) | Valchor Treatment of Lichen Planopilaris | Week 24 | -66.7 | Full Range -100.0 to 66.7 | percentage of change from baseline |
| Change in Dermatology Quality of Life Index (DQLI) | Valchor Treatment of Lichen Planopilaris | -2 | Full Range -11 to 2 | score on a scale | |
| Change in Follicular Units | Valchor Treatment of Lichen Planopilaris | -9.1 | Full Range -25.8 to 37.5 | percent change | |
| Change in Mean Follicular Density | Valchor Treatment of Lichen Planopilaris | -9.0 | Full Range -25.8 to 37.6 | percent change |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Valchor Treatment of Lichen Planopilaris | 12 | |
| Overall Study | COMPLETED | Valchor Treatment of Lichen Planopilaris | 8 | |
| Overall Study | NOT COMPLETED | Valchor Treatment of Lichen Planopilaris | 4 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Contact dermatitis | Skin and subcutaneous tissue disorders | Valchor Treatment of Lichen Planopilaris | 11 | 12 | 11 |
| other | Severe Itching | Skin and subcutaneous tissue disorders | Valchor Treatment of Lichen Planopilaris | 1 | 12 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Valchor Treatment of Lichen Planopilaris | 0 | 12 |
| Total, other adverse events | Valchor Treatment of Lichen Planopilaris | 11 | 12 |
| Total, serious adverse events | Valchor Treatment of Lichen Planopilaris | 0 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03417141
GET https://conductscience.org/api/trials/v1/NCT03417141/registered